Bioventix PLC (BVXP) Rating Reiterated by FinnCap
Bioventix PLC (LON:BVXP)‘s stock had its “corporate” rating reissued by equities researchers at FinnCap in a research report issued to clients and investors on Tuesday. They presently have a GBX 1,450 ($17.99) price target on the biotechnology company’s stock. FinnCap’s target price points to a potential upside of 9.19% from the stock’s current price.
Bioventix PLC (LON:BVXP) opened at 1328.00 on Tuesday. Bioventix PLC has a one year low of GBX 899.50 and a one year high of GBX 1,600.00. The firm has a 50-day moving average of GBX 1,385.40 and a 200-day moving average of GBX 1,121.62. The company’s market capitalization is GBX 67.06 million.
The firm also recently declared a dividend, which was paid on Friday, November 11th. Stockholders of record on Thursday, October 27th were issued a dividend of GBX 46 ($0.57) per share. The ex-dividend date of this dividend was Thursday, October 27th. This is a boost from Bioventix PLC’s previous dividend of $16.50. This represents a dividend yield of 3.15%.
In other news, insider Ian James Nicholson sold 2,000 shares of the stock in a transaction on Friday, November 18th. The stock was sold at an average price of GBX 1,300 ($16.13), for a total transaction of £26,000 ($32,254.06).
Bioventix PLC Company Profile
Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.
Receive News & Stock Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related stocks with our FREE daily email newsletter.